Hostname: page-component-745bb68f8f-f46jp Total loading time: 0 Render date: 2025-01-09T01:31:55.519Z Has data issue: false hasContentIssue false
  • English
  • Français

Side effects of moclobemide in depressed patients refractory to other treatments

Published online by Cambridge University Press:  13 June 2014

T J Fahy
T J Fahy*
Affiliation:
The Department of Psychiatry, University College Hospital, Galway, Ireland
Get access Rights & Permissions [Opens in a new window]

Abstract

Fifteen consecutive cases of moderate and severe depression were treated with moclobemide in recommended dosage and followed for six months. Eleven developed excitatory side effects including agitation, insomnia, restlessness and aggressivity; five patients reported unreality experiences. Subject to confirmation, these findings, together with indications of similar side effects in published studies and in non fatal overdose, raise the possibility that the potential of moclobemide to cause excitation in depressed patients refractory to other treatments may have been hitherto underestimated.

Keywords

MoclobemideSide effects
Type
Clinical & Brief Reports
Information
Irish Journal of Psychological Medicine , Volume 10 , Issue 1 , February 1993 , pp. 24 - 27
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Manerix [Roche data sheet]. Hertfordshire: Roche Products, 1991.Google Scholar
2.Angst, J, Stabl, M. Eficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 1992; 106: S109–S113.CrossRefGoogle Scholar
3.Larsen, JK, Holm, P, Heyer, E, Mejlhede, A, Mikkelsen, PL, Olesen, A, Schaumburg, E. Moclobemide and clomipramine in reactive depression. Acta Psychiat Scand 1989; 79: 530–536.CrossRefGoogle ScholarPubMed
4.Amrein, R, Guntert, TW, Dingemanse, J, Lorscheid, T, Stabl, M, Schmid-Burgk, W. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 1992; 106: S24–S31.CrossRefGoogle ScholarPubMed
5.Hill, S. Roche Products Ltd. Personal communications to the author, October 1992.Google Scholar
6.Versiani, M, Nardi, AE, Figueira, ILV, Stabl, M. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiat Scand 1990; 360 (Suppl): 24–28.CrossRefGoogle ScholarPubMed
7.Versiani, M, Oggero, U, Alterwain, P, Capponi, R, Dajas, F, Heinze-Martin, G, et al.A double-blind comparative trial of Moclobemide v. Imipramine and placebo in major depressive episodes. Br J Psychiatry 1992; 155 Suppl 6: 72–7.CrossRefGoogle Scholar
8.Baumhackl, U, Biziere, K, Fischbach, R, Geretsegger, C, Hebenstreit, G, Radmayr, E, Stabl, M. Efficacy and tolerability of Moclobemide compared with Imipramine in depressive disorder (DSM-III): An Austrian double-blind, multicentre study. Br J Psychiatry 1989; 155 Suppl 6: 78–83.CrossRefGoogle Scholar
9.Bougerol, T, Uchida, C, Gachoud, JP, Kohler, M, Mikkelsen, H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM-III); A French/Swiss double-blind trial. Psychopharmacology 1992; 106: S102–S108.CrossRefGoogle ScholarPubMed
10.Stabl, M, Biziere, K. Schmidt-Burgh, W, Amrein, R. Review of comparative clinical trials: moclobemide vs. tricyclic antidepressants vs. placebo in depressive states. J Neurol Transm 1989; 28 (Suppl): 77–89.Google ScholarPubMed